Solbec granted patent
Thursday, 29 September, 2005
Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.
Last month Solbec was granted a US patent based on the same inventive material. The RBP receptor is over-expressed in mammalian cancer cells, but not in healthy cells, and explains why Solbec's Coramsine is selective in targeting cancer cells.
The term of the patent runs until February 2023.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
